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Antigens of Lung Cancer: Results of the Third
International Workshop on Lung Tumor and
Differentiation Antigens
Rolf A. Stahel, Walter R. Gilks, Thomas Schenker*
This commentary describes the results of the "cluster"
analysis of the Third International Workshop on Lung Tumor
and Differentiation Antigens, which was held under the
patronage of the International Association for the Study of Lung
Cancer in Zurich, September 8-11, 1993. Antibodies and an-
tigens were grouped into clusters on the basis of the phenotypic
reaction of antibodies with cell lines and tissues, with the main
focus being the characterization of lung cancer antigens and an-
tibodies. This workshop extended the findings of two previous
International Workshops on Small-Cell Lung Cancer Antigens
that were held in London in 1987 (/) and 1990 (2). Seven
clusters were described at these two earlier workshops (an
eighth cluster, cluster-3, had been described at the first work-
shop, but was rejected at the second workshop). Eight new
clusters were described at this workshop.
The Third International Workshop on Lung Tumor and Dif-
ferentiation Antigens had three goals. The first goal was to iden-
tify clusters of antibodies based on similar reactivity against cell
lines and tissues in order to define antigens associated with lung
tumors and lung differentiation. In contrast to the two previous
workshops, which were largely restricted to antibodies reacting
with small-cell lung cancer, it was decided to broaden the scope
of the workshop to include antibodies reacting with all types of
lung tumors or normal lung tissues. This decision was made
after determining (a) that many of the antibodies examined
during the previous workshops reacted with non-small-cell lung
cancer, (b) that there was a growing interest in studies on
bronchial differentiation and dysplasia, and (c) that many more
clusters of antibodies are likely to be found with reactivities that
would be classified as being restricted to small-cell lung cancer.
The second goal of the workshop was to exchange information
about the molecular nature and function of the members of pre-
viously defined clusters. The third goal was to exchange infor-
mation about preclinical and clinical studies in lung cancer with
antibodies or conjugates.
Since the first workshop, our knowledge of particular anti-
gens recognized by clustered antibodies has greatly increased.
This increase is primarily due to the molecular characterization
of some of the antigens—in particular those of cluster-1 [iden-
tified as the neural cell adhesion molecule (2)], cluster-2 [iden-
tified as epithelial glycoprotein-2 or the product of the GA733-2
gene (2,5)], and cluster-w4 [shown to be identical to the
Leukocyte Workshop antigen CD24, with the exception of one
amino acid (4)]. As the complementary DNA (cDNA) probes
encoding these antigens were available, it was decided to add
the screening of a panel of cells transfected with the genes en-
coding the respective antigens to the cluster analysis conducted
by the workshop participants.
The details of the workshop, including the results of the cen-
tral data analysis, the statistical analysis, a list of the participat-
ing laboratories, and individual papers describing the antigens or
preclinical and clinical studies with the antibodies, are being
published in a supplement to the International Journal of Cancer
(5). Here, we summarize the major findings of this workshop,
including the cluster analysis and the present state of knowledge
regarding the antigens identified and assigned to clusters.
Twenty-eight laboratories submitted antibodies to the work-
shop. Of 60 new antibodies or antibodies that had not been as-
signed to clusters at the previous workshops, 32 could be placed
in clusters at the current workshop. The decisions regarding the
assignment to particular clusters or the definition of new clusters
were made entirely on the basis of phenotypic observations on
cell lines and tissues. As in the previous workshops, provisional
clusters were designated with the prefix "w" if no more than two
antibodies from the same laboratory formed the cluster and the
nature of their antigen had not been fully defined. The an-
tibodies included in the present workshop were assigned to 15
clusters, with 8 of these clusters (cluster-lC and clusters 9-15)
being newly defined. Cluster-1 and cluster-8 were each assigned
six antibodies at this workshop; however, of all the clusters,
cluster-1 continues to have the largest total number of an-
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tibodies. Cluster-6 and cluster-8, which have been provisional
clusters defined primarily on the basis of oligosaccharide bind-
ing at the second workshop, have now for the first time been
defined by phenotypic analysis. The antibodies defining these
clusters and the present knowledge about the respective antigens
are summarized in Table 1.
Cluster-1
Four antibodies from four laboratories were grouped with two
antibodies observed to react with cluster-1 antigens in the pre-
vious workshop. With the exception of antibody Mab735, which
was described as reacting with an epitope of 10 or more units of
a-(2,8)-/V-linked polysialic acid side chains of NCAM, all anti-
bodies were found to react with NCAM transfectants of mouse
L-cells. The tissue distribution confirmed strong binding to
small-cell lung cancer, neuroblastoma, nerve, central nervous
system, Leydig cells of the testis, and thyroid follicles; little or
no binding to epithelial cells was observed. All antibodies lost
reactivity in routinely fixed tissues. As expected, binding was
seen on subpopulations of lymphoid cells, with the exception of
antibody SEN7, which has been reported to have little or no
binding on peripheral blood lymphocytes (6). Collaborative
work by participants in the workshop resulted in a topographic
mapping of antigenic epitopes on NCAM (7).
Cluster-lC
Two antibodies from the same laboratory that had been raised
directly against human NCAM clustered very closely and were
designated to cluster-1C. Both bind to intracellular NCAM
epitopes and thus have a different pattern of reactivity than
cluster-1 antibodies. Antibody KD11 was shown to recognize
the most C-terminal part of transmembrane isoforms; antibody
MG5 specifically recognizes an undecapeptide in the N-terminal
region of exon 18 (8).
Table 1. Cluster analysis of the Third International Workshop on Lung Tumor
and Differentiation Antigens
Cluster
1
1C
2
4
5A
6
w7
g
9
10
11
12
13
14
w!5
Antibodies*
ITK2,Mab735,RNL-l,
MB-2, SEN36, SEN7
KD-ll.MG-5
MOC-31
SWA-1.1
SEN31
MLuC-1, ABL364, MLuC-5,
KM 132
NCC-ST-439, NCC-CO-450
CC49, B72.3, CC83, 1.291,
2.304, A-80
KL-6, KM432, CTM01, ICR2
RNL-2, RNL-3
44-3A6, KM 195
MW207, FBP146, FBP343,
FBP458, FBP741
RS7, MR54
EMD5590,ICR16,
ICR12
ME-l.ME-2
Antigen
NCAM, extracell. domains
NCAM, intracell. domains
EGP-2/GA733-2
CD24
Sialoglycoproteins
LeY hapten
High-molecular-weight mucins
Mucins (TAG-72)
Mucins (MUC1)
Neurone-specific proteins
40-kd membrane
Folic acid receptor
EGP-1/GA733-1
EGF-receptor
pl85ncu
Mesothelial membrane antigen
•Eleven of the antibodies are controls (ITK2, RNL-1, SEN36, MOC-31,
SWA-11, SEN31, NCC-ST-439, NCC-CO-450, A-80, RNL-2, and 44-3A6).
peripheral blood mononuclear cells and lymphoid cell lines.
Protein sequence analysis revealed a heavily glycosylated and
unusually short protein of 80 amino acids, virtually identical to
the recently cloned leukocyte activation antigen CD24 except
for a single valine-alanine substitution resulting from a single
base polymorphism. Biochemical analysis has confirmed the
presence of a phosphoinositol tail by which the antigen is
anchored in the cell membrane. The linear peptide sequence
leucine-alanine-proline on the protein core of the antigen lo-
cated close to the phosphoinositol anchor has been identified as
one of the epitopes (9).
Cluster-2
No new antibodies grouped with the cluster-2 control by
phenotypic cluster analysis. Since the last workshop, progress
has been made in the molecular characterization of this antigen
by several laboratories (3,8). The antigen named epithelial
glycoprotein-2 or the product of the GA733-2 gene was cloned
both from a lung adenocarcinoma cell cDNA expression library
using the monoclonal antibody KS1/4 as probe and from a colon
carcinoma cell cDNA expression library using the antibodies
GA733 and HEA 125 as probes. At the workshop, the current
knowledge about the epitopes recognized by cluster-2 anti-
bodies as well as evidence for a putative 30-kd ligand with
specificity for cluster-2 antigen was presented.
Cluster-4
No new antibodies reacting with cluster-4 antigen were iden-
tified. The antigen has been cloned from a small-cell lung can-
cer expression library (5). Cluster-4 message was found to be
highly overexpressed in small-cell lung cancer compared with
Cluster-5 and Cluster 5A
No new antibodies reacting with cluster-5 and cluster 5A an-
tigens were identified at this workshop. The antigens recognized
by cluster-5 and cluster-5A antibodies represent a group of N-
linked sialoglycoproteins strongly expressed in about 50% of
small-cell lung cancer tissues, with little expression on epithelial
cells and no expression on white blood cells. Cluster-5 and
cluster-5A antigens are coexpressed in small-cell lung cancer
cell lines and tissues, but their molecular relationship has long
remained undefined. Evidence for the simultaneous expression
of the cluster-5 and cluster-5A epitopes on a single membrane
molecule which is shed in low quantities into the serum of
patients with small-cell lung cancer has been obtained by im-
munological means. This was accomplished by first generating a
mouse monoclonal anti-anti-idiotype antibody against a rat
monoclonal anti-idiotype antibody in the cluster-5 system and
then by conducting heterologous cluster-5 and cluster-5A anti-
body sandwich assays on the sera of patients with small-cell
lung cancer (70).
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Cluster-6
Four antibodies from three laboratories were found to group
together at this workshop. Antibody MLuC-1 recognition of the
blood group LeY hapten as an antigen has been described (77).
In the previous workshop, two antibodies that were not available
to the current workshop defined cluster-w6 by both weak pheno-
typic clustering and by oligosaccharide binding. The availability
of additional antibodies that grouped closely together allowed
the discontinuation of the provisional "w" designation. The tis-
sue distribution for cluster-6 antibodies reported in this
workshop includes binding to small-cell lung cancer and non-
small-cell lung cancer, broad epithelial reactivity, and lack of
binding to neural tissues and white blood cells.
Cluster-w7
Two control antibodies from the same laboratory that react
with cluster-w7 antigen were used by the panel of this
workshop. One of the antibodies clustered with the negative
controls, suggesting loss of immunoreactivity. No new antibody
clustering with the remaining cluster-w7 control was identified.
Cluster-8
Five antibodies from two laboratories clustered together with the
cluster-w8 control antibody A-80. In the previous workshop,
cluster-w8 antibodies grouped only weakly by phenotypic analysis
but exhibited similarities in oligosaccharide-binding studies;
biochemical analyses indicated that they bound the blood group A
trisaccharide. At this workshop, the phenotypic clustering was
much closer. The tissue distribution for cluster-8 antibodies
reported in this workshop included binding to non-small-cell lung
cancer, broad epithelial reactivity, and lack of reactivity with neural
tissues or with white blood cells. A previous study (72) has charac-
terized the antibodies B72.3, CC49, and CC83, which recognize a
high-molecular-weight mucin designated TAG72.
Cluster-9
Four antibodies from four laboratories grouped together and
were newly designated to cluster-9. One of these antibodies,
CTM01, is reported to recognize the mucin MUC-1. Another
antibody that recognizes an epitope, termed BrE-3, on the pep-
tide core of MUC-1 was phenotypically only weakly associated
with cluster-9. A similarly weak association with cluster-9 was
also observed for a second antibody, RS5-4H6, which had been
characterized as reacting with undefined high-molecular-weight
mucins. It is likely that this finding might be due to different
carbohydrate epitopes that can be present on the same mucin
core protein. The tissue distribution of cluster-9 antibodies
demonstrated binding to small-cell lung cancer and non-small-
cell lung cancer, broad epithelial reactivity, white blood cell
reactivity, and lack of binding to neural cells.
CIuster-10
Two antibodies from one laboratory closely grouped together
and were newly designated to cluster-10. The antibodies recog-
nize a family of intracellular neuron-specific proteins ranging
from 135 to 25 kd in molecular mass. These proteins have been
shown to derive from one gene, NSP (13). Phenotypic analysis
at this workshop confirmed the intracellular expression of this
antigen predominantly in neuroendocrine tissues, including
small-cell lung cancer. The reaction was lost in routinely fixed
tissues. Evidence for the subcellular localization of these
proteins in the endoplasmatic reticulum was presented.
Cluster-11
Two IgG antibodies from two laboratories phenotypically
grouped together and were newly designated to cluster-11. The
antigen of one of these antibodies, 44-3A6, has been biochemi-
cally described as a 40-kd membrane-associated protein (14). At
the workshop, it was reported that the gene coding for this nega-
tively charged protein has recently been cloned and termed Nag
gene (14). No sequence homologies have been identified so far.
The phenotypic analysis obtained at the workshop demonstrated
lack of immunofluorescence activity on viable cells. Examina-
tion of tissues revealed antibody binding to non-small-cell lung
cancer, limited epithelial reactivity, and lack of neural or white
blood cell reactivity.
Cluster-12
Five antibodies from two laboratories grouped together and
were newly designated to cluster-12. The antibodies of the FBP
series have been obtained by immunization with human folate
binding protein, a membrane glycoprotein with specific affinity
for folic acid and methotrexate (75). Phenotypic analysis in the
current workshop demonstrated binding to non-small-cell lung
cancer (in particular, adenocarcinoma), limited epithelial reac-
tivity, and some binding to monocytes. No antibody binding was
seen in routinely fixed tissues. Additional antibodies, generated
against ovarian carcinoma, were recently demonstrated to recog-
nize human folate-binding proteins by expression cloning. Since
antifolate agents, including methotrexate, enter the cell through
the folate-binding protein, the expression of these antigens in
tumor cells might be important to maintain the sensitivity of
tumor cells to these drugs.
Cluster-13
Two antibodies from two laboratories of the same institution
closely grouped together and were designated to cluster-13. The
antigen recognized by antibody RS7 has been affinity purified
and partially sequenced. Sequence analysis indicated identity to
the product of the GA733-1 gene (76). Together with the gene
GA733-2, which encodes epithelial glycoprotein-2 or cluster-2
antigen, GA733-1 forms a family of genes coding for type I
transmembrane proteins of unknown function (77). No other
antibodies against the GA733-1 gene product (epithelial
glycoprotein-1) had been identified previously. Phenotypic
analysis at this workshop demonstrated antigen expression on
non-small-cell lung cancer, limited epithelial expression, and
lack of expression in neural tissues or white blood cells. No
binding was seen on routinely fixed tissues.
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Cluster-14
Three antibodies from two laboratories grouped together and
were designated to cluster-14. Two of these antibodies
(EMD5590 and ICR16) (18) were shown to bind to the external
domain of the epidermal growth factor receptor, and one has
been shown to be specific for the external domain of pl85neu
(ICR12). Despite recognizing different molecules, the three anti-
bodies had a similar binding pattern in the cell lines and tissues
examined during this workshop. Binding was seen in non-
small-cell lung cancer, mesothelioma, and a limited number of
epithelia but not on normal neural tissues or white blood cells.
None of the antibodies bound on routinely fixed tissues.
Cluster-wl5
Two antibodies raised in one laboratory against a meso-
thelioma cell line closely grouped together and were designated
to cluster-wl5. Nothing is known about their respective an-
tigens, except that they are expressed on the external cell
membrane surface. Phenotypic analysis in the workshop
demonstrated binding to non-small-cell lung cancer (in par-
ticular, squamous cell carcinoma) and mesothelioma, with only
limited epithelial reactivity. Also, weak binding to neural cells
and tissues has been observed. The antibodies lost activity in
routinely fixed tissues. The antibody ME1 strongly stains all
malignant mesothelioma tissues and a proportion of poorly dif-
ferentiated lung adenocarcinomas (19).
Judged on the ability to define clusters of antibodies and an-
tigens, the Third International Workshop has been a success,
doubling the number of recognized clusters from seven to 15.
The classification system developed at these workshops comple-
ments the classification system developed by others for leuko-
cyte antigens because the majority of antibodies directed against
solid tumor antigens were selected by their lack of reactivity
with white blood cells. The strength of the statistical analysis
based on phenotypic reactivity of the antibodies was docu-
mented (20) and was found to ideally complement the clustering
of antibodies determined by the analysis of cells transfected
with the cDNA of cloned antigens.
The clustering of antibodies has both stimulated and facili-
tated investigations on their potential clinical use in diagnosis
and therapy. The use of a common nomenclature allows a better
comparison of investigations by different laboratories and
potentially avoids duplicate work. Most importantly, the work-
shop has brought together investigators working on similar
molecules and has fostered fruitful collaborations between dif-
ferent groups. This effort, hopefully, should increase the pace of
advances, not only by improving our understanding of the roles
that individual antigens play in lung biology and carcinogenesis,
but also through provision of information that might soon be
utilized in lung cancer detection and treatment.
With the addition of antibodies to non-small-cell lung cancer,
the current workshop has increased in scope compared with the
previous workshops. Results communicated at the workshop, how-
ever, clearly suggest that most of the antigens clustered have also
been identified in other solid tumors, exemplified by cluster-2 and
cluster-8 in colon carcinoma, cluster-12 in ovarian carcinoma, and
cluster-12 in breast cancer. It has thus become evident that in order
to facilitate the identification of additional antibodies and anti-
gens to group in new and existing clusters, a useful and common
nomenclature must be further developed, not only for the benefit
of lung cancer specialists, but also for the benefit of those study-
ing other solid tumors and lung diseases. Specifically, a future
workshop might include research groups working with antigens
in other solid tumors. Laboratories interested in contributing to
the development of such a workshop should contact us.
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